AstraZeneca: The longest survival data from the global phase III trial of early-stage EGFR mutant lung cancer was released. Teresa reduced the overall risk of death of patients treated with stage II-IIIA by 47% in eight years.

AstraZeneca: The longest survival data from the global phase III trial of early-stage EGFR mutant lung cancer was released. Teresa reduced the overall risk of death of patients treated with stage II-IIIA by 47% in eight years.